Akaal Pharma is a privately held biotechnology company based in Australia, focused on the discovery and development of innovative drug therapies targeting unmet clinical needs.
Akaal Pharma have developed an internal proprietary library of over 100 novel small molecules with a number as potent and selective modulators of the Sphingosine 1-Phosphate receptor-1 (S1P1). As a target, S1P1 plays a key role in inflammatory and autoimmune disorders, and potentially other therapeutic areas.
Takp-119 & Oakp-11: Targeted S1P1 Modulator
Akaal Pharma’s lead candidates, Takp-119 and Oakp-11, have demonstrated a differentiated or breakthrough profile compared to existing S1P1 – drugs, with superior efficacy and safety in preclinical and clinical studies. Several key advantages of Takp-119 and Oakp-11 include high receptor selectivity, strong receptor activity with an excellent safety margin, minimal and reversible lymphopenia, cardiovascular safety, and a favourable pharmacokinetic profile.